It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The trimeric HIV-1 Envelope protein (Env) mediates viral-host cell fusion via a network of conformational transitions, with allosteric elements in each protomer orchestrating host receptor-induced exposure of the co-receptor binding site and fusion elements. To understand the molecular details of this allostery, here, we introduce Env mutations aimed to prevent CD4-induced rearrangements in the HIV-1 BG505 Env trimer. Binding analysis and single−molecule Förster Resonance Energy Transfer confirm that these mutations prevent CD4-induced transitions of the HIV-1 Env. Structural analysis by single−particle cryo-electron microscopy performed on the BG505 SOSIP mutant Env proteins shows rearrangements in the gp120 topological layer contacts with gp41. Displacement of a conserved tryptophan (W571) from its typical pocket in these Env mutants renders the Env insensitive to CD4 binding. These results reveal the critical function of W571 as a conformational switch in Env allostery and receptor-mediated viral entry and provide insights on Env conformation that are relevant for vaccine design.
Here, using cryo-EM and smFRET, Henderson et al. show how tryptophan 571 in the HIV-1 Env acts as a conformational switch during receptor-mediated viral entry and design HIV-1 Env proteins that cannot undergo conformational changes. This has important implications for HIV-1 vaccine design.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Duke University School of Medicine, Department of Medicine, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
2 Yale University School of Medicine, Department of Microbial Pathogenesis, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
3 Duke University, Department of Computer Science, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
4 Duke University School of Medicine, Department of Immunology, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
5 Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
6 Department of Health and Human Services, Genome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, USA (GRID:grid.26009.3d)
7 Weill Cornell Medicine, Department of Physiology and Biophysics, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, USA (GRID:grid.5386.8)
8 Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Surgery, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
9 Duke University, Department of Computer Science, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Biochemistry, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University, Department of Electrical and Computer Engineering, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
10 Duke University School of Medicine, Department of Medicine, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Immunology, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
11 Duke University School of Medicine, Department of Medicine, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Pathology, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)